Tess O’Meara, Hematology/Oncology Fellow at Dana-Farber Cancer Institute, shared a post on LinkedIn:
“Excited to to share that my editorial, mentored and co-authored by Dr. Harold Burstein, is published in Annals of Oncology today to accompany the updated overall survival results from the monarchE clinical trial.
Practice-affirming monarchE data were presented at ESMO – European Society for Medical Oncology in Berlin today, showing improvement in patient survival at 7 years with the addition of CDK4/6i abemaciclib to endocrine therapy for high-risk, early-stage ER+ breast cancer.
We tackle the questions:
– Which patients benefit most from the addition of adjuvant CDK4/6i?
– Which patients might be spared the extra side effects, like diarrhea and low blood counts, by foregoing these therapies?
– How do we interpret overall survival results from adjuvant ER+ breast cancer trials, where recurrence can occur years after upfront treatment?”
Title: Long-term Outcomes with Adjuvant CDK4/6 Inhibitors: Who Benefits Most?
Authors: T.A. O’Meara, H.J. Burstein
You Can Also Read:
ESMO 2025 Day 1 Highlights Not to Miss
POTOMAC Trial at ESMO 2025: Durvalumab Plus BCG Improves Outcomes in High-Risk NMIBC
ESMO Announces the 2025 Society Award Winners
